Shentong Technology Group (605228.SH) plans to launch a restricted stock and stock option incentive plan for 2025.
Shentong Technology (605228.SH) disclosed the restricted stock and stock option incentive plan for 2025 (draft), intending to grant a total of 14 million shares to incentive objects, involving RMB A-share common stocks, accounting for 3.24% of the total share capital of the company at the time of the incentive plan announcement. Among them, 9.2 million shares of stock options are granted for the first time, and 2 million shares of restricted stock are granted for the first time. The total number of incentive objects granted for the first time is 117 people, with an exercise price of 14.58 yuan per share for the granted stock options and a grant price of 7.29 yuan per share for the granted restricted stock.
Shentong Technology Group (605228.SH) disclosed its 2025 Restricted Stock and Stock Option Incentive Plan (draft), planning to grant a total of 14 million shares (units) of equity to incentive objects. The types of stocks involved are RMB A shares, accounting for 3.24% of the total share capital of the company at the time of the incentive plan announcement. Among them, 9.2 million stock options are granted for the first time, and 2 million restricted stocks are granted for the first time. The total number of incentive objects granted for the first time is 117 people. The exercise price of the stock options granted for the first time is 14.58 yuan per unit, and the grant price of the restricted stocks is 7.29 yuan per share.
Related Articles
CHINA LESSO (02128) and Guangdong Liansu Electric have signed a parts supply agreement.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.
CHINA LESSO (02128) and Guangdong Liansu Electric have signed a parts supply agreement.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.
